Enanta Pharmaceuticals Inc., of Watertown, Mass., reported results from a phase Ia/b trial testing its FXR agonist EDP-305 in healthy volunteers and patients with presumed non-alcoholic fatty liver disease. The pharmacokinetic data supports once daily oral dosing of EDP-305.